Lactic acid bacterial composition for modulating immune cell differentiation and/or reducing pro-inflammatory cytokine secretion and use thereof
A lactic acid bacterial composition for modulating immune cell differentiation and/or reducing pro-inflammatory cytokine secretion includes: (a) a Limosilactobacillus reuteri GL-104 strain; and (b) a Lacticaseibacillus rhamnosus F-1 strain; wherein the GL-104 strain is deposited at the China Center for Type Culture Collection with a deposition number CCTCC M209138, and the F-1 strain is deposited at the China Center for Type Culture Collection with a deposition number CCTCC M2011124. Additionally, a method for treating or preventing allergic rhinitis by administering the foregoing composition to a subject in need thereof is also provided.
1 . A method for treating or preventing allergic rhinitis, comprising:
administering a lactic acid bacterial composition to a subject in need of reducing production of pro-inflammatory cytokine CXCL 10 by an immune cell of the subject or increasing a ratio of CD206 to CD86 on a surface of the immune cell of the subject, the composition comprising: (a) a Limosilactobacillus reuteri GL-104 strain; and (b) a Lacticaseibacillus rhamnosus F-1 strain; wherein the GL-104 strain is deposited at the China Center for Type Culture Collection with a deposition number CCTCC M209138; wherein the F-1 strain is deposited at the China Center for Type Culture Collection with a deposition number CCTCC M2011124, wherein relative to total colony forming unit of the GL-104 strain and the F-1 strain, the GL-104 strain is present at 30%, and the F-1 strain is present at 70%.
2 . The method as claimed in claim 1 , wherein the GL-104 strain is a viable strain or an inactivated strain, and the F-1 strain is a viable strain or an inactivated strain.
3 . The method as claimed in claim 1 , wherein the lactic acid bacterial composition further comprises: (c) an excipient, diluent, or carrier.
4 . The method as claimed in claim 3 , wherein the excipient, diluent, or carrier is a food-acceptable excipient, diluent, or carrier, or a pharmaceutical-acceptable excipient, diluent, or carrier.
5 . The method as claimed in claim 1 , wherein the composition is administered at a total bacterial count of the GL-104 strain and the F-1 strain from 10 6 to 10 10 CFU/kg of body weight of the subject per day.